JV is devoted to the development and production of biosimilars, compounds close in structure to a biologic, which is made from proteins

The Nasdaq-listed biotechnology firm approached Samsung to sell its shares, which could be valued at more than 50 trillion won ($42 billion)

Japan’s Eisai saw its US listed shares rise 56% – up by more than Biogen’s 38% jump after US regulators...